AdAlta Pty Ltd (AdAlta) has had its key patent granted by the Japanese Patent and Trademark Office which protects the development of i-bodies.
The patent, entitled “Binding moieties based on shark IgNAR domains”, provides an exclusivity period until June 2025. The patent specifically covers a method of modifying a number of human proteins called I-set domains to include features of the shark single domain antibody and this modified protein is what AdAlta calls the i-body. In addition to this newly granted patent in Japan, AdAlta has other granted patents in the USA and Australia and patents pending in other jurisdictions.
Sam Cobb, CEO of AdAlta said “The grant of this patent relating to the i-body platform underpins AdAlta’s unique drug discovery platform, to which we have identified our lead i-body for treatment of fibrotic diseases.”
i-bodies are a new class of therapeutic proteins that contain the unique structural and functional properties of the single domain shark antibody, including extreme stability and the ability to access alternative epitopes such as those of GPCR and ion channel targets. AdAlta is focused on developing the i-body based therapeutics against various disease targets exploiting some of the key benefits i-bodies have over conventional antibodies and other antibody fragments.
AdAlta is developing a pipeline of i-bodies, with a focus on treatment of fibrotic diseases and cancer. Recent animal studies have demonstrated positive in vivo data and AdAlta is developing an improved therapy for the treatment of fibrosis, prevalent in 45-50% of all diseases. AdAlta is currently raising funding to progress its lead to the clinic.